Psilocybin vs. SSRIs: The NEJM Comparison Study Explained
About This Video
A careful breakdown of the Imperial College London escitalopram vs. psilocybin head-to-head trial published in the New England Journal of Medicine (2021). The study compared 25mg psilocybin (two sessions) against six weeks of daily escitalopram (Lexapro, 10-20mg), with both groups receiving identical talking therapy support.
The primary outcome (HAM-D depression scale) showed statistical equivalence between groups — but the video explains why this is not the same as showing psilocybin and escitalopram are equally effective. The primary endpoint was chosen before the trial; psilocybin showed significant advantages on multiple secondary measures including emotional blunting reduction, wellbeing, meaning/purpose, social connectedness, and frequency of positive emotions.
The key limitation explained: the trial was functionally unblinded — participants almost certainly knew which treatment they received. The video gives an honest assessment of what can and cannot be concluded from this study and why it was nonetheless a landmark.
Key Takeaways
- NEJM 2021 trial: psilocybin (2 sessions) vs. escitalopram (6 weeks daily) for depression.
- Primary endpoint (HAM-D): no statistically significant difference between groups.
- Secondary measures: psilocybin significantly outperformed escitalopram on wellbeing, emotional blunting, meaning, and social connection.
- Critical limitation: functional unblinding — nearly all participants likely knew their treatment assignment.
- The trial does not prove psilocybin is superior — it shows promising signals on quality-of-life measures that SSRIs typically do not affect.
Dive Deeper
Continue exploring this topic on ShroomTube: